Biocon, India's largest biotech company is focused on delivering affordable innovation.
It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Biocon's key innovations include an indigenous recombinant human insulin based on proprietary fermentation technology, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon.
Its aspiration to become a US$ 1 billion company by FY18 is fuelled by five powerful growth accelerators, small molecules, biosimilars, branded formulations, novel molecules, and research services with a focus on emerging markets.
Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries.
Biocon Ltd: Fully integrated biopharmaceutical company
|2013||Biocon Unveils Biocon Academy - A center of excellence for advanced learning in applied biosciences.|
|2008||Biocon is the 7th largest biotech employer in the world (Med Ad News).|
|2000||Biocon establishes Clinigene, India's first clinical research organisation (CRO) to pursue clinical R&D.|
|1989||Biocon is the first Indian biotech company to receive US funding for proprietary technologies.|
|1979||Biocon is the first Indian company to manufacture and export enzymes to USA and Europe.|